As part of the programme (click here to download the schedule at a glance), we are pleased to offer an additional day (Sunday, May 27) prior to the start of the formal Congress dedicated to Satellite Symposia sponsored by industry partners on topics of significant interest to our members and delegates.

For this meeting we are delighted to have three Symposia on very different topics, but all are extremely  interesting and informative. Registration for the Satellite Symposia involves a small ($50.00 USD) additional fee but one registration permits attendance at all three Symposia.


goedlogo1_small.jpg

SATELLITE 1:
An Update on the Role of EPA and DHA for Brain Health

Sponsored by GOED
An update on the role/functions of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in human brain health will be explored. The presentations will explore the current state of the science and identify research gaps in the following areas: mental illness, Attention Deficit (Hyperactivity) Disorder, cognitive function and brain injury.


DSM_MasterLogo_FullColor_small.jpg

SATELLITE 2:
Arachidonic and docosahexaenoic acids in infant development
Sponsored by DSM
The biological functions of arachidonic acid (ARA) and docosahexaenoic acid (DHA) in mammalian development, both human and animal, will be highlighted in this symposium.  An international panel of thought leaders in this area will be assembled for these presentations.


SANCILIO.png

SATELLITE 3:
Drug Development of Omega-3 Fatty acids: Does one size fit all?

Sponsored by Sancilio & Co Inc.
Interest by the pharmaceutical and biotechnology sectors in the development of Omega-3 fatty acids and derivatives as registered pharmaceutical products continues to grow. It is estimated that at least 20 companies are known to be looking at new Pharma targets using EPA and/or DHA based compounds in more than 30 therapeutic areas (GOED 2014), and yet many aspects of their clinical pharmacology remain unclear. Absorption rates and bioavailability are complex processes subject to wide variability between subjects and conditions, and as a minimum to meet regulatory requirements a more detailed understanding of pharmacokinetics and dynamics is required. These limitations pose challenges for any sponsor wishing to embark upon developing these compounds in any particular therapeutic area, challenges which are magnified by the regulatory requirements for drug approval.  This satellite is therefore designed to give a better understanding of  the clinical pharmacology of omega-3 fatty acids, to identify potential paths for their use in disease specific treatments and how to meet the regulatory hurdles which may be present.